Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Futura Medical ( (GB:FUM) ) has issued an update.
Futura Medical announced the successful passing of all resolutions at its recent Annual General Meeting, including the appointment and re-election of directors and the re-appointment of its auditor. This development is expected to strengthen the company’s governance and operational framework. The company continues to focus on expanding its market presence with its innovative sexual health products, supported by strategic partnerships in major markets such as the US and Europe.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £125.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative and clinically proven sexual health products. Its core strength lies in research, development, and commercialization of topically delivered gel formulations, with key products including Eroxon, WSD4000, and Eroxon Intense. The company addresses significant unmet needs in the sexual health market, particularly with its lead product, Eroxon, which is the only topical gel treatment for erectile dysfunction available over the counter.
Average Trading Volume: 484,727
Technical Sentiment Signal: Sell
Current Market Cap: £27.19M
For detailed information about FUM stock, go to TipRanks’ Stock Analysis page.